Immunovirotherapy for the treatment of glioblastoma.
Publication
, Journal Article
Cheema, TA; Fecci, PE; Ning, J; Rabkin, SD
Published in: Oncoimmunology
January 1, 2014
We have recently described a new murine model of glioblastoma, generated by the implantation of syngeneic glioblastoma stem cells into immunocompetent mice, that recapitulates the salient histopathological and immunological features of the human disease. We employed this model to demonstrate the multifaceted activity of an oncolytic herpes simplex virus genetically modified to express interleukin-12, G47∆-IL12.
Duke Scholars
Published In
Oncoimmunology
DOI
ISSN
2162-4011
Publication Date
January 1, 2014
Volume
3
Issue
1
Start / End Page
e27218
Location
United States
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3204 Immunology
- 1112 Oncology and Carcinogenesis
- 1107 Immunology
Citation
APA
Chicago
ICMJE
MLA
NLM
Cheema, T. A., Fecci, P. E., Ning, J., & Rabkin, S. D. (2014). Immunovirotherapy for the treatment of glioblastoma. Oncoimmunology, 3(1), e27218. https://doi.org/10.4161/onci.27218
Cheema, Tooba A., Peter E. Fecci, Jianfang Ning, and Samuel D. Rabkin. “Immunovirotherapy for the treatment of glioblastoma.” Oncoimmunology 3, no. 1 (January 1, 2014): e27218. https://doi.org/10.4161/onci.27218.
Cheema TA, Fecci PE, Ning J, Rabkin SD. Immunovirotherapy for the treatment of glioblastoma. Oncoimmunology. 2014 Jan 1;3(1):e27218.
Cheema, Tooba A., et al. “Immunovirotherapy for the treatment of glioblastoma.” Oncoimmunology, vol. 3, no. 1, Jan. 2014, p. e27218. Pubmed, doi:10.4161/onci.27218.
Cheema TA, Fecci PE, Ning J, Rabkin SD. Immunovirotherapy for the treatment of glioblastoma. Oncoimmunology. 2014 Jan 1;3(1):e27218.
Published In
Oncoimmunology
DOI
ISSN
2162-4011
Publication Date
January 1, 2014
Volume
3
Issue
1
Start / End Page
e27218
Location
United States
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3204 Immunology
- 1112 Oncology and Carcinogenesis
- 1107 Immunology